PT-141 (Bremelanotide) and Nicotine: What Women Need to Know About This Interaction

What Is PT-141 (Bremelanotide) and Why Does It Matter for Women?

Bremelanotide, sold under the brand name Vyleesi, is the only subcutaneous injectable approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally, not genitally. Unlike sildenafil, which targets penile vasculature, bremelanotide acts on melanocortin-4 receptors in the hypothalamus to generate sexual desire before a sexual encounter.

The FDA approval covers acquired, generalized HSDD in premenopausal women only. "Acquired" means the condition was not lifelong. "Generalized" means it occurs in most situations, not only with specific partners or contexts.

HSDD affects an estimated 8 to 14 percent of premenopausal women in the United States, making it the most common female sexual dysfunction by prevalence. Yet clinical trials for bremelanotide enrolled exclusively premenopausal women, which means data for perimenopausal and postmenopausal women is extrapolated at best.

How Bremelanotide Works in the Female Brain

The hypothalamic melanocortin system modulates appetite, mood, and sexual motivation. In women, this system is influenced by estrogen. Estrogen upregulates melanocortin-4 receptor sensitivity, which may partly explain why bremelanotide was studied in premenopausal rather than postmenopausal women first.

Preclinical data show that estrogen potentiates the pro-sexual effects of melanocortin agonists in female rats, raising the biologically plausible hypothesis that the drug's efficacy may diminish with declining estrogen in perimenopause or post-menopause. This is not confirmed in human trials, and the FDA label does not address it directly.

The Approved Indication and What It Does Not Cover

Bremelanotide is not approved for:

• Low desire caused by a medical condition or medication (these require treating the root cause)
• HSDD in postmenopausal women
• Male sexual dysfunction
• Enhancement of desire in women who do not have HSDD

If you are perimenopausal and experiencing low desire, the evidence-based first line is hormone therapy or, for genitourinary syndrome, vaginal estrogen, not bremelanotide.

The Nicotine and PT-141 Interaction: What the Evidence Actually Shows

The core concern is pharmacodynamic, not pharmacokinetic. Nicotine and bremelanotide do not share metabolic pathways, so nicotine does not meaningfully change how fast your body clears bremelanotide or vice versa. The real issue is that both agents independently raise blood pressure, and the effects add up.

What Bremelanotide Does to Your Blood Pressure

The FDA-approved prescribing information reports that a single 1.75 mg subcutaneous dose of bremelanotide produces a mean maximum increase of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure. This peak typically occurs 4 to 12 hours after the injection and resolves by 12 hours in most women.

In the Phase 3 RECONNECT trials (Study 301 and Study 302), which enrolled a combined 1,247 premenopausal women with HSDD, transient hypertension was among the most clinically notable findings. Women with pre-existing uncontrolled hypertension were excluded from those trials, meaning real-world users with borderline blood pressure have essentially no controlled-trial safety data to draw on.

What Nicotine Does to Your Blood Pressure

Each cigarette delivers a bolus of nicotine that activates the adrenergic nervous system. The acute hemodynamic response includes a 5 to 10 mmHg rise in systolic blood pressure and a 10 to 15 beats-per-minute increase in heart rate that peaks within minutes and persists for 20 to 40 minutes. Nicotine replacement products (patches, gum, lozenges, inhalers) and electronic cigarettes produce qualitatively similar, if often smaller, acute pressor effects.

Chronic nicotine use also causes endothelial dysfunction and arterial stiffness, raising baseline cardiovascular risk independent of the acute pressor effect.

When You Combine the Two

No controlled clinical study has specifically examined bremelanotide plus nicotine in women. This is a genuine evidence gap, and honest labeling requires saying so plainly.

What can be modeled from existing data: if bremelanotide raises systolic BP by 6 mmHg and a cigarette raises it by another 5 to 10 mmHg in the same window, a woman with a resting systolic of 125 mmHg could plausibly reach 136 to 141 mmHg transiently. For most healthy young premenopausal women with normal cardiovascular function, that window is uncomfortable but not dangerous. For a woman with hypertension, migraine with aura, or established cardiovascular disease, that window carries meaningful risk.

The WomanRx clinical team uses this decision framework for women who smoke or use nicotine products and are considering bremelanotide:

| Clinical Profile | Practical Guidance | |---|---| | Healthy, normotensive, light smoker (<5 cigarettes/day) | Avoid smoking for at least 2 hours before and 4 hours after injection; monitor BP | | Moderate-to-heavy smoker, normotensive | Discuss with prescriber; consider home BP monitoring on the first two uses | | Any nicotine user with BP >130/80 mmHg | Bremelanotide is contraindicated per label; add nicotine as a compounding risk factor | | Nicotine replacement (patch/gum), normotensive | Lower acute pressor risk than cigarettes; still disclose to prescriber | | Nicotine vape user | Acute pressor effect is variable and often underestimated; treat similarly to cigarette use |

Other Interactions You Should Know: A Broader Profile for Women

Nicotine is not the only substance that interacts with bremelanotide. Because women often ask "can I drink on PT-141?" this section addresses alcohol and other common interactions together.

Alcohol and PT-141

The FDA label does not specifically prohibit alcohol, but alcohol is a central nervous system depressant while bremelanotide is a CNS-active melanocortin agonist. The most practically relevant concern is that nausea is the most common adverse effect of bremelanotide, reported in approximately 40 percent of women in the RECONNECT trials, and alcohol significantly worsens nausea for most people. Pre-medicating with ondansetron 8 mg oral 30 minutes before injection can reduce nausea, but combining that with alcohol adds its own sedation and antiemetic-interference considerations.

There is no pharmacokinetic evidence that alcohol changes bremelanotide's peak concentration or half-life. The concern is additive symptom burden, not a metabolic clash.

Naltrexone and Opioid-Related Medications

Bremelanotide is metabolized via peptide hydrolysis rather than CYP450 pathways, which substantially limits classic drug metabolism interactions. Naltrexone (used in bupropion/naltrexone for weight management, which many women with PCOS or metabolic syndrome take) does not appear to significantly alter bremelanotide's pharmacokinetics, but data are limited.

Indomethacin and NSAIDs

The FDA label specifically flags indomethacin: co-administration with bremelanotide increases the rate and extent of indomethacin absorption. Women who use indomethacin for endometriosis-related pain or dysmenorrhea should be aware of this specific interaction. Other NSAIDs (ibuprofen, naproxen) are not specifically listed, but the mechanism suggests a potential class effect worth monitoring.

Antihypertensive Medications

Because bremelanotide transiently raises blood pressure, women already on antihypertensive therapy are in a catch-22. The drug is contraindicated in women with uncontrolled hypertension or known cardiovascular disease per the FDA label. If you are on a beta-blocker, ACE inhibitor, or ARB for blood pressure, adding a drug that acutely raises BP requires explicit clinician review, not assumption of safety.

Sex-Specific Pharmacology: How Being a Woman Shapes the Bremelanotide Experience

Body Composition and Drug Distribution

Women typically have a higher body-fat percentage than men of similar weight. Because bremelanotide is a peptide administered subcutaneously, the injection site and subcutaneous tissue depth can affect absorption rate. The drug was studied exclusively in women, so the approved 1.75 mg dose already reflects female pharmacokinetics. No dose adjustment is recommended based on BMI in the current label, but women with obesity were underrepresented in the RECONNECT trials (mean BMI was approximately 27 kg/m²).

The Menstrual Cycle and Desire Variability

Sexual desire in women with HSDD fluctuates across the menstrual cycle. Desire typically peaks around ovulation when estrogen and a small LH-driven testosterone surge coincide. Women in the late luteal phase often report lower desire regardless of treatment. This means bremelanotide's efficacy may appear to vary across the cycle, not because the drug is failing but because baseline desire is genuinely lower in certain hormonal windows.

No sub-group analysis from the RECONNECT trials stratified outcomes by menstrual cycle phase. The 2019 Journal of Sexual Medicine report on Study 301 reported improvement in the Female Sexual Function Index desire domain score and reduction in distress on the Female Sexual Distress Scale-Desire/Arousal/Orgasm, but cycle-phase analysis was not performed.

PCOS and Bremelanotide

Women with polycystic ovary syndrome often have baseline androgen excess, insulin resistance, and irregular cycles. PCOS is the most common endocrine disorder in reproductive-age women, affecting 6 to 12 percent of women of reproductive age in the United States. Low desire in PCOS is often multifactorial: mood disorders, body image concerns, hyperandrogenism causing acne and hirsutism that affect self-esteem, and in some cases, medications like spironolactone that may blunt libido.

Bremelanotide's melanocortin mechanism is theoretically interesting in PCOS because melanocortin signaling is also involved in energy balance and GnRH pulsatility, but no PCOS-specific trials have been conducted with bremelanotide. Prescribers should not assume efficacy in PCOS-related HSDD is equivalent to the RECONNECT trial population.

Perimenopause: Why the Label Does Not Cover You

If you are in perimenopause, experiencing vasomotor symptoms, irregular cycles, and declining estrogen, bremelanotide is not FDA-approved for your life stage. The RECONNECT trials required participants to be premenopausal by FSH and clinical criteria. The Menopause Society's 2023 position statement on sexual function recommends hormone therapy, vaginal estrogen for GSM, and ospemifene or local lidocaine for dyspareunia as evidence-based first steps. Bremelanotide is not mentioned as a recommended option for perimenopausal or postmenopausal women in that statement.

Pregnancy, Lactation, and Contraception: A Required Warning

Bremelanotide is contraindicated in pregnancy. This is not a soft caution. The FDA label requires that a pregnancy test be performed before the first dose and that women use effective contraception.

Pregnancy Data

Animal reproduction studies showed fetal harm at doses approximately 1.5 times the recommended human dose based on AUC. Darkened fetal fur and alterations in reproductive performance were observed in rat studies. Human pregnancy data are absent; the drug was not studied in pregnant women, and no pregnancy registry has been established.

If you discover you are pregnant and have used bremelanotide, contact your OB-GYN immediately. The risk level from a single inadvertent dose before pregnancy was recognized is unknown, but the drug should be stopped immediately.

Lactation

There are no human data on bremelanotide transfer into breast milk. Given its peptide structure, some transfer is biologically plausible, though gastrointestinal degradation in the infant might limit systemic exposure. The FDA label states that the developmental and health benefits of breastfeeding should be weighed against the potential risk. Given the absence of data, most women's-health clinicians advise against using bremelanotide while breastfeeding. If you are postpartum and experiencing low libido while nursing, this is an extremely common and hormonally driven experience (prolactin suppresses estrogen and desire), and addressing it begins with hormonal evaluation rather than bremelanotide.

Contraception Requirements

Because of the fetal risk signal, any woman of reproductive age using bremelanotide should use effective contraception consistently. "Using it occasionally" when desire returns is not sufficient safety planning. Discuss contraceptive method with your provider before starting bremelanotide.

Who This Drug Is Right For, and Who It Is Not

Women Who May Be Appropriate Candidates

• Premenopausal women with a confirmed diagnosis of acquired, generalized HSDD
• Women whose low desire causes personal distress (distress is part of the diagnostic criteria)
• Women who have not responded to or are not candidates for psychological or couples therapy alone
• Women with normal or well-controlled blood pressure
• Women who are not pregnant, not trying to conceive, and using reliable contraception

Women for Whom Bremelanotide Is Not the Right Tool

• Postmenopausal women: no approved indication, insufficient safety data
• Women with uncontrolled hypertension or established cardiovascular disease: contraindicated per FDA label
• Pregnant women: contraindicated
• Breastfeeding women: insufficient safety data; most clinicians advise avoidance
• Women whose low desire is situational (tied to relationship conflict, specific partner, or context): this is not acquired generalized HSDD
• Women whose low desire is caused by a treatable underlying condition (hypothyroidism, depression, medication side effects): treat the cause first
• Heavy smokers with blood pressure above 130/80 mmHg: the combined cardiovascular burden makes this a high-risk combination

Practical Dosing and Administration for Women

Bremelanotide is supplied as a single-use autoinjector delivering 1.75 mg subcutaneously. You inject it into the abdomen or thigh 45 minutes before anticipated sexual activity.

Key practical points:

• Maximum one dose per 24 hours, and no more than one dose per sexual encounter
• If there is no improvement in sexual desire after 8 weeks of as-needed use, the prescribing information recommends discontinuation
• Nausea is the most common reason women stop the drug; ondansetron pre-treatment is a clinically used strategy, though it is off-label for this purpose
• Flushing, headache, and hyperpigmentation (particularly of the face, gums, and breasts) can occur with repeated use; the hyperpigmentation may be permanent
• Do not use if you have taken any meal within 30 minutes; absorption variability is greater in the fed state

If you smoke or use nicotine products, the most practical harm-reduction step is to avoid nicotine for at least 2 hours before and 4 hours after injection, specifically during the window when bremelanotide's pressor effect is at its peak.

What the Evidence Gap Means for You

Women have been historically underrepresented in drug trials, and bremelanotide is a partial exception. The RECONNECT program enrolled only women, which is a genuine strength. But enrollment focused on premenopausal women with HSDD, excluding those with cardiovascular risk factors, heavy smokers, and women outside the reproductive years.

The specific question of nicotine-plus-bremelanotide hemodynamic risk has never been studied in a controlled trial. What exists is mechanistic reasoning from separately established pharmacodynamic effects. That is not nothing, but it is not the randomized data clinicians prefer.

The American College of Obstetricians and Gynecologists' practice bulletin on female sexual dysfunction notes that HSDD is underdiagnosed and undertreated in clinical practice. It does not specifically address the nicotine interaction.

Women who smoke and have HSDD deserve a nuanced conversation with their prescriber, not a blanket refusal or a blanket "it's probably fine." The honest answer is: the combined cardiovascular burden adds up, the evidence to quantify the combined risk precisely does not exist yet, and your personal blood pressure trajectory on the day you use bremelanotide matters more than any population-level average.

If you want to use bremelanotide and you smoke, check your blood pressure at home before injecting. A resting systolic above 130 mmHg on the day you plan to use it is a reason to hold the dose and contact your provider.